Whistleblower Rebuffs Counterclaim for Disclosing Confidential Information
Client Alert | 1 min read | 05.20.16
In U.S. ex rel. Cieszynski v. LifeWatch Servs. (N.D. Ill., May 9), the court dismissed the defendant’s counterclaim against a former employee and FCA whistleblower, ruling that the whistleblower’s disclosure of protected patient information fell within the public policy protections for whistleblowers. As described in a post on the Whistleblower Watch Blog, there has been an increase in recent years of FCA defendants raising counterclaims based on breaches of confidentiality agreements, and this will likely remain an active area of litigation until the courts clearly define what documents an FCA whistleblower can take from an employer and how the whistleblower can use those documents to support FCA allegations.
Contacts
Insights
Client Alert | 4 min read | 01.07.26
On December 17, 2025, the U.S. Food and Drug Administration (FDA) issued a request for information (RFI) on a proposal designed to help the FDA engage more directly with innovative, venture-backed companies focused on biotechnology, medical devices, AI, and regulatory technology.[i]The RFI includes 19 questions, with responses due by 2:00 p.m. ET on January 18, 2026.
Client Alert | 3 min read | 01.07.26
CMMC for AI? Defense Policy Law Imposes AI Security Framework and Requirements on Contractors
Client Alert | 3 min read | 01.07.26
New Year, Same CIPA Uncertainty – When Will the Appellate Courts Enter the Chat?
Client Alert | 11 min read | 01.07.26



